Open, phase IIIb, multicentric, safety and reactogenicity study of GlaxoSmithKline Biologicals' reduced antigen content combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix) administered as a booster dose to healthy children 4-6 years of age according to the international recommended prescribing information

Trial Profile

Open, phase IIIb, multicentric, safety and reactogenicity study of GlaxoSmithKline Biologicals' reduced antigen content combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix) administered as a booster dose to healthy children 4-6 years of age according to the international recommended prescribing information

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2006

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top